Michael Maris, MD
Dermatology · Dallas, TXNPI 1225104672
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Galderma Laboratories, L.p. accounts for 92.7% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $290 and has fallen 68.0% since, to $93 in 2025. That places this record below the midpoint for dermatology clinicians in TX, where the typical reported total is $4,085.
Across 39 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$722
- AbbVie$24
- Incyte Corporation$18
- Pfizer$14
Across 11 payments — averaging $5775.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$64K
What the payments were for
- Food & beverage$778100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 36 | $722 |
| AbbVie | 1 | $24 |
| Incyte Corporation | 1 | $18 |
| Pfizer | 1 | $14 |
How this compares
$778 in reported general payments places this provider in the 20th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Betamethasone Valerate | 32 | $885 |
| Ketoconazole | 46 | $777 |
| Clobetasol Propionate | 13 | $580 |
| ValacyclovirValacyclovir Hcl | 18 | $526 |
| Triamcinolone Acetonide | 27 | $358 |
| Mupirocin | 36 | $200 |
| Doxycycline Hyclate | 14 | $196 |
| Cephalexin | 16 | $59 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Dallas
- Jennifer CatherDallas$1.3M
- Ross RaduskyDallas$1.2M
- Joseph MerolaDallas$1.2M
- So Yeon PaekDallas$812K
- Martin MenterDallas$512K
- Mary HornerDallas$448K
- Donald GlassDallas$347K
- William AbramovitsDallas$325K
- Mary FleischliDallas$153K
- Adean KingstonDallas$141K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.